Travere Therapeutics, Inc.
US ˙ NasdaqGM ˙ US89422G1076

SecurityTVTX / Travere Therapeutics, Inc.
InstitutionUbs Asset Management Americas Inc
Latest Disclosed Ownership137,025 shares
Latest Disclosed Value $ 4,071,013
Ubs Asset Management Americas Inc reports 36.55% decrease in ownership of TVTX / Travere Therapeutics, Inc.

On May 13, 2026 - Ubs Asset Management Americas Inc filed a 13F-HR form disclosing ownership of 137,025 shares of Travere Therapeutics, Inc. (US:TVTX) valued at $4,071,013 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 215,951 shares of Travere Therapeutics, Inc.. This represents a change in shares of -36.55% during the quarter. The current value of the position is $6,193,530 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 137,025 -78,926 -36.55 4,071 -50.66 0.0001
2026-02-13 2025-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 215,951 70,024 47.99 8,251 136.62 0.0017
2025-11-14 2025-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 145,927 -299,630 -67.25 3,488 -47.12 0.0008
2025-08-14 2025-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 445,557 378,960 569.03 6,594 452.72 0.0013
2025-05-19 2025-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 66,597 -95,006 -58.79 1,193 -57.62 0.0003
2025-02-14 2024-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 161,603 -1,572 -0.96 2,815 23.36 0.0007
2024-11-14 2024-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 163,175 -15,574 -8.71 2,283 55.34 0.0006
2024-08-14 2024-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 178,749 74,769 71.91 1,469 83.40 0.0004
2024-05-15 2024-03-31 13F TRAVERE THERAPEUTICS EQUITY US CM 89422G107 103,980 4,555 4.58 802 -10.30 0.0003
2024-02-14 2023-12-31 13F TRAVERE THERAPEUTICS EQUITY US CM 89422G107 99,425 0 0.00 894 0.56 0.0004
2023-11-13 2023-09-30 13F TRAVERE THERAPEUTICS EQUITY US CM 89422G107 99,425 10,880 12.29 889 -55.40 0.0004
2023-08-11 2023-06-30 13F TRAVERE THERAPEUTICS EQUITY US CM 89422G107 88,545 0 0.00 1,991 0.00 0.0010
2023-05-15 2023-03-31 13F TRAVERE THERAPEUTICS EQUITY US CM 89422G107 88,545 24,967 39.27 1,991 48.92 0.0010
2023-02-14 2022-12-31 13F TRAVERE THERAPEUTICS EQUITY US CM 89422G107 63,578 1,152 1.85 1,337 -13.07 0.0007
2022-11-14 2022-09-30 13F TRAVERE THERAPEUTICS EQUITY US CM 89422G107 62,426 -3,739 -5.65 1,538 -4.05 0.0009
2022-08-12 2022-06-30 13F TRAVERE THERAPEUTICS EQUITY US CM 89422G107 66,165 -1,016 -1.51 1,603 -7.39 0.0008
2022-05-16 2022-03-31 13F TRAVERE THERAPEUTICS EQUITY US CM 89422G107 67,181 3,993 6.32 1,731 -11.73 0.0007
2022-02-14 2021-12-31 13F THERAPEUTICS EQUITY US CM 89422G107 63,188 11,413 22.04 1,961 56.25 0.0008
2021-11-15 2021-09-30 13F THERAPEUTICS EQUITY US CM 89422G107 51,775 -1,779 -3.32 1,256 60.69 0.0005
2021-08-16 2021-06-30 13F THERAPEUTICS EQUITY US CM 89422G107 53,554 4,169 8.44 781 -36.66 0.0003
2021-05-14 2021-03-31 13F THERAPEUTICS EQUITY US CM 89422G107 49,385 10,700 27.66 1,233 16.98 0.0005
2021-03-01 2020-12-31 13F/A-1 THERAPEUTICS EQUITY US CM 89422G107 38,685 0 0.00 1,054 47.62 0.0005
2021-02-17 2020-12-31 13F RETROPHIN EQUITY US CM 761299106 38,685 0 714 0.0674
2020-11-13 2020-09-30 13F RETROPHIN EQUITY US CM 761299106 38,685 4,970 14.74 714 3.78 0.0004
2020-08-14 2020-06-30 13F RETROPHIN EQUITY US CM 761299106 33,715 3,455 11.42 688 56.01 0.0004
2020-05-15 2020-03-31 13F RETROPHIN EQUITY US CM 761299106 30,260 -943 -3.02 441 -0.45 0.0003
2020-02-14 2019-12-31 13F RETROPHIN EQUITY US CM 761299106 31,203 884 2.92 443 26.21 0.0003
2019-11-14 2019-09-30 13F RETROPHIN EQUITY US CM 761299106 30,319 15,721 107.69 351 19.80 0.0002
2019-08-15 2019-06-30 13F RETROPHIN EQUITY US CM 761299106 14,598 -9,170 -38.58 293 -45.44 0.0002
2019-05-14 2019-03-31 13F RETROPHIN EQUITY US CM 761299106 23,768 14,598 159.19 538 159.42 0.0004
2019-02-13 2018-12-31 13F RETROPHIN EQUITY US CM 761299106 9,170 -7,700 -45.64 208 -57.23 0.0002
2018-11-13 2018-09-30 13F RETROPHIN EQUITY US CM 761299106 16,870 0 0.00 485 5.45 0.0004
2018-08-14 2018-06-30 13F RETROPHIN EQUITY US CM 761299106 16,870 7,852 87.07 460 128.36 0.0004
2018-05-14 2018-03-31 13F RETROPHIN EQUITY US CM 761299106 9,018 9,018 202 0.0002
2017-03-09 2016-12-31 13F/A-1 RETROPHIN EQUITY US CM 761299106 0 -19,500 -100.00 0 -100.00
2016-11-04 2016-09-30 13F RETROPHIN EQUITY US CM 761299106 19,500 0 0.00 436 25.65 0.0005
2016-11-29 2016-06-30 13F/A-1 RETROPHIN EQUITY US CM 761299106 19,500 8,100 71.05 347 122.44 0.0004
2016-08-09 2016-06-30 13F RETROPHIN EQUITY US CM 761299106 19,500 347
2016-05-12 2016-03-31 13F RETROPHIN EQUITY US CM 761299106 11,400 -800 -6.56 156 -33.62 0.0002
2016-02-12 2015-12-31 13F RETROPHIN EQUITY US CM 761299106 12,200 12,200 235 0.0003
2015-10-29 2015-09-30 13F RETROPHIN EQUITY US CM 761299106 0 -10,500 -100.00 0 -100.00
2015-08-12 2015-06-30 13F RETROPHIN EQUITY US CM 761299106 10,500 10,500 348 0.0003
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.